Work

SWOG S2107: Randomized phase II trial of encorafenib and cetuximab with or without nivolumab for patients with previously treated, microsatellite stable, BRAF V600E metastatic and/or unresectable colorectal cancer.

Year: 2024

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2024.42.16_suppl.tps3640

Authors: Van K. Morris, Katherine A. Guthrie, Scott Kopetz, Rimini Breakstone, Thomas Benjamin Karasic, Zishuo Ian Hu, Sarah Colby, Marwan Fakih, Sepideh Gholami, Philip Jordan Gold, E. Gabriela Chiorean, Philip A. Philip

Institutions: The University of Texas MD Anderson Cancer Center, Fred Hutch Cancer Center, Brown University, Miriam Hospital, University of Pennsylvania, City Of Hope National Medical Center, Northwell Health, University of Washington, Henry Ford Health, Henry Ford Hospital

Language: English

Topic: Colorectal Cancer Treatments and Studies

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4399736694

Cites:

Cited by: 3

Related to: 10